VRTX

Vertex Pharmaceuticals

Health Care

Biotechnology

Boston, Massachusetts

Balance Sheet 36 Accounts • 5 Years

Account	2024	2023	2022	2021	2020
end	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets - CashAndCashEquivalents	$4.6B	$10.4B	$10.5B	$6.8B	$6.0B
Assets - MarketableSecuritiesCurrent	$1.5B	$849.2M	$274.5M	$729.9M	$670.7M
Assets - AccountsReceivable	$1.6B	$1.6B	$1.4B	$1.1B	$885.4M
Assets - Inventories	$1.2B	$738.8M	$460.6M	$353.1M	$280.8M
Assets - PrepaidExpensesAndOtherCurrentAssets	$665.7M	$623.7M	$553.5M	$545.8M	$308.3M
Assets - TotalCurrentAssets	$9.6B	$14.1B	$13.2B	$9.6B	$8.1B
Assets - Property,PlantAndEquipment	$1.2B	$1.2B	$1.1B	$1.1B	$958.5M
Assets - Goodwill	$1.1B	$1.1B	$1.1B	$1.0B	$1.0B
Assets - IntangibleAssets(net,ExcludingGoodwill)	$825.9M	$839.9M	$603.6M	$400.0M	$400.0M
Assets - DeferredTaxAssets	$2.9B	$2.2B	$1.6B	$1.3B	$1.2B
Assets - OperatingLeaseAssets	$1.4B	$293.6M	$347.4M	$330.3M	$325.6M
Assets - FinanceLeaseAssets	$57.9M	$272.8M	$315.5M	$400.1M	$431.2M
Assets - OtherNoncurrentAssets	$999.3M	$895.3M	$409.6M	$110.8M	$49.3M
Assets - TotalNoncurrentAssets	$2.6B	$1.5B	$1.5B	$1.4B	$1.3B
Assets - TotalAssets	$22.5B	$22.7B	$18.2B	$13.4B	$11.8B
Liabilities - AccountsPayable	$413.0M	$364.9M	$303.9M	$195.0M	$155.1M
Liabilities - AccruedLiabilities	$2.8B	$2.7B	$2.1B	$1.7B	$1.4B
Liabilities - OperatingLeaseLiabilitiesCurrent	$87.1M	$33.1M	$48.6M	$33.3M	$10.5M
Liabilities - FinanceLeaseLiabilitiesCurrent	$5.2M	$50.6M	$40.8M	$46.9M	$42.4M
Liabilities - OtherCurrentLiabilities	$363.0M	$527.2M	$311.5M	$268.4M	$317.4M
Liabilities - TotalCurrentLiabilities	$3.6B	$3.5B	$2.7B	$2.1B	$1.9B
Liabilities - OperatingLeaseLiabilitiesNoncurrent	$1.5B	$348.6M	$379.5M	$377.4M	$350.5M
Liabilities - FinanceLeaseLiabilitiesNoncurrent	$112.8M	$376.1M	$430.8M	$509.8M	$539.0M
Liabilities - DeferredTaxLiabilitiesNoncurrent	$285.5M	$300.5M	$297.5M	$261.5M	$236.6M
Liabilities - ContingentConsiderationLiabilityNoncurrent	$76.9M	$77.4M	$114.4M	$186.5M	$189.6M
Liabilities - OtherNoncurrentLiabilities	$901.8M	$877.7M	$685.8M	$303.3M	$108.4M
Liabilities - TotalLiabilities	$6.1B	$5.1B	$4.2B	$3.3B	$3.1B
Equity - PreferredStock	$0	$0	$0	$0	$0
Equity - CommonStock	$2.6M	$2.6M	$2.6M	$2.5M	$2.6M
Equity - RetainedEarnings(deficit)	$9.6B	$10.1B	$6.5B	$3.2B	$858.7M
Equity - AccumulatedOtherComprehensiveIncome(loss)	$127.8M	$-14.3M	$800.0K	$15.9M	$-68.5M
Equity - TotalStockholdersEquity	$16.4B	$17.6B	$13.9B	$10.1B	$8.7B
Equity - TotalLiabilitiesAndStockholdersEquity	$22.5B	$22.7B	$18.2B	$13.4B	$11.8B
Equity - TotalLiabilitiesandEquity	$22.5B	$22.7B	$18.2B	$13.4B	$11.8B
Validation - L+E Components Sum Difference	$0	$0	$0	$0	$0

Income Statement 19 Accounts • 5 Years

Account	2024	2023	2022	2021	2020
end	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
IncomeStatement - Revenues - NetRevenues/ProductSales	$11.0B	$9.9B	$8.9B	$7.6B	$6.2B
IncomeStatement - CostsAndExpenses - CostOfGoodsSold/CostOfSales	$1.5B	$1.3B	$1.1B	$904.2M	$736.3M
IncomeStatement - CostsAndExpenses - ResearchAndDevelopmentExpense	$3.6B	$3.2B	$2.5B	$3.1B	$1.8B
IncomeStatement - CostsAndExpenses - Selling,GeneralAndAdministrative	$1.5B	$1.1B	$944.7M	$840.1M	$770.5M
IncomeStatement - OtherIncomeExpense - OperatingIncome(loss)	$-232.9M	$3.8B	$4.3B	$2.8B	$2.9B
IncomeStatement - OtherIncomeExpense - InterestExpense	$25.2M	$38.8M	$43.5M	$47.4M	$58.2M
IncomeStatement - OtherIncomeExpense - Gain(loss)OnInvestments/securities	$-9.5M	$-7.5M	$-149.1M	$17.1M	$136.2M
IncomeStatement - OtherIncomeExpense - OtherNonoperatingIncome(expense)	$-86.1M	$-22.8M	$-164.8M	$4.9M	$296.6M
IncomeStatement - OtherIncomeExpense - Income(loss)BeforeIncomeTaxes	$248.5M	$4.4B	$4.2B	$2.7B	$3.1B
IncomeStatement - IncomeTax - IncomeTaxExpense(benefit)	$784.1M	$760.2M	$910.4M	$388.3M	$405.2M
IncomeStatement - IncomeTax - EffectiveTaxRate	$3	$0	$0	$0	$0
IncomeStatement - NetIncomeAndEps - NetIncome(loss)	$-535.6M	$3.6B	$3.3B	$2.3B	$2.7B
IncomeStatement - NetIncomeAndEps - NetIncome(loss)AttributableToCompany	$-535.6M	$3.6B	$3.3B	$2.3B	$2.7B
IncomeStatement - NetIncomeAndEps - BasicEarningsPerShare	$-2	$14	$13	$9	$10
IncomeStatement - NetIncomeAndEps - DilutedEarningsPerShare	$-2	$14	$13	$9	$10
IncomeStatement - NetIncomeAndEps - WeightedAverageSharesOutstandingBasic	$257.9M	$257.7M	$256.1M	$257.7M	$259.8M
IncomeStatement - NetIncomeAndEps - WeightedAverageSharesOutstandingDiluted	$257.9M	$260.5M	$259.1M	$259.9M	$263.4M
IncomeStatement - NetIncomeAndEps - ComprehensiveIncome(loss)	$-393.5M	$3.6B	$3.3B	$2.4B	$2.6B

Cash Flow Statement 22 Accounts • 5 Years

Account	2024	2023	2022	2021	2020
end	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
CashFlow - OperatingActivities - NetIncome	$-535.6M	$3.6B	$3.3B	$2.3B	$2.7B
CashFlow - OperatingActivities - DepreciationAndAmortization	$207.2M	$181.3M	$148.3M	$125.6M	$109.5M
CashFlow - OperatingActivities - ShareBasedCompensation	$698.5M	$581.2M	$491.3M	$441.4M	$429.5M
CashFlow - OperatingActivities - DeferredIncomeTaxes	$-348.8M	$-536.5M	$-275.9M	$-154.6M	$277.3M
CashFlow - OperatingActivities - ChangesInOperatingAssetsAndLiabilities	$906.1M	$1.2B	$1.4B	$508.0M	$1.1B
CashFlow - OperatingActivities - NetCashFromOperatingActivities	$-492.6M	$3.5B	$4.1B	$2.6B	$3.3B
CashFlow - InvestingActivities - CapitalExpenditures(pp&e)	$297.7M	$200.4M	$204.7M	$235.0M	$259.8M
CashFlow - InvestingActivities - PurchasesOfMarketableSecurities/investments	$7.4B	$3.8B	$692.7M	$528.2M	$431.4M
CashFlow - InvestingActivities - ProceedsFromSales/maturitiesOfMarketableSecurities/investments	$4.5B	$839.1M	$920.0M	$499.3M	$372.3M
CashFlow - InvestingActivities - AcquisitionsOfBusinesses,NetOfCash	$0	$0	$295.9M	$0	$0
CashFlow - InvestingActivities - OtherInvestingActivities	$54.0M	$31.0M	$47.8M	—	—
CashFlow - InvestingActivities - NetCashFromInvestingActivities	$-3.8B	$-3.1B	$-321.1M	$-340.9M	$99.4M
CashFlow - FinancingActivities - PaymentsForRepurchaseOfCommonStock	$1.2B	$427.6M	$0	$1.4B	$539.1M
CashFlow - FinancingActivities - PaymentsRelatedToTaxWithholdingForShareBasedCompensation	$405.0M	$226.1M	$172.0M	$135.9M	$200.3M
CashFlow - FinancingActivities - OtherFinancingActivities	$6.2M	$1.8M	$3.5M	$5.7M	$-1.8M
CashFlow - FinancingActivities - NetCashFromFinancingActivities	$-1.5B	$-562.2M	$-67.7M	$-1.5B	$-505.3M
CashFlow - CashReconciliationAndSupplemental - EffectOfExchangeRateChangesOnCash	$-42.6M	$26.9M	$-29.2M	$-13.4M	$20.6M
CashFlow - CashReconciliationAndSupplemental - NetChangeInCash	$-5.8B	$-139.7M	$3.7B	$811.2M	$2.9B
CashFlow - CashReconciliationAndSupplemental - IncomeTaxesPaid	$1.1B	$1.7B	$1.1B	$476.3M	$191.8M
CashFlow - CashReconciliationAndSupplemental - InterestPaid	$30.5M	$43.1M	$52.3M	$56.3M	$54.5M
CashFlow - CashReconciliationAndSupplemental - RightOfUseAssetsObtainedForLeases(nonCash)	$1.1B	$2.4M	$58.6M	$36.3M	$293.6M

Vertex Pharmaceuticals

Balance Sheet 36 Accounts • 5 Years

Income Statement 19 Accounts • 5 Years

Cash Flow Statement 22 Accounts • 5 Years

Stock Market Data (1 Year) Live Yahoo Finance Data

Recent Price History